Medical Device | April 05, 2022
Agilent joins AMBIC to advance biomanufacturing
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Announces pilot project for rapid, remote diagnosis of tuberculosis
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Subscribe To Our Newsletter & Stay Updated
